The role of adjuvant chemotherapy for non-small cell lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 3, 2005, Pages 298-303

  Gurubhagavatula, Sarada ^a,b,c   Lynch, Thomas J ^b,c  

^a NORTH SHORE MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant; Chemotherapy; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; UFT; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURGERY; CLINICAL TRIAL; DRUG TOLERABILITY; EARLY CANCER; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 22144475120     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-871988     Document Type: Review

References (28)

1. American Cancer Society. Cancer Facts and Figures 2005. Available at: http://www.cancer.org/downloads/STT/CAFF200Sf4PWSecured.pdf
2. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996; 77:2464-2470
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606
4. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903
5. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717
7. Pairolero P, Williams D, Bergstralh E, Piehler J, Bernatz P, Payne W. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331-338
8. Martini N, Bains M, Burt M, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-129
9. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer: Implications for screening. Chest 1992;101:1013-1018
10. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:1-15, 71-85
11. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95: 105-112
12. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-944
13. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730
14. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
15. Scagliotti G, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003;95: 1453-1461
16. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721
17. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360
18. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract 7019]. Proc Am Soc Clin Oncol 2004;23(Suppl):17
19. Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non-small cell lung cancer (NSCLC) Intergroup JBR. 10 [abstract 7018]. Proc Am Soc Clin Oncol 2004;23(Suppl):17
20. Pfisters K. Discussion of CALBG Protocol 9633. 2004 American Society of Clinical Oncology Annual Meeting
21. American Cancer Society. Detailed Guide: Lung Cancer. Available at: http://www.cancer.org/docroot/cri/content/ cri_2_4_1x_what_are_the_key_statistics_for_lung_cancer_26. asp
22. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients [abstract 7068]. Proc Am Soc Clin Oncol 2004;23:630
23. Fossella F, Pereira J, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003;21:3016-3024
24. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1S39-1S49
25. Lynch TJ, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer patients to gefitinib. N Engl J Med 2004;350:2129-2139
26. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
27. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefinitib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311
28. Sandler A, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract LBA4]. Proc Am Soc Clin Oncol 2005;23(Suppl)